20374 Seneca Meadows Parkway
About Intrexon Corporation
Through the engineering of biology, Intrexon is helping to address some of the world’s most pressing challenges and is working with industry and government leaders to realize a better, healthier planet. Today our platform is delivering new therapies in health, supplying unique solutions to address global energy demand, developing unparalleled features and productivity advancements in food, creating innovative applications for consumers, and helping to restore and protect the environment.
To execute on its mission, Intrexon has integrated a suite of technologies and expertise across a number of cellular systems to drive development and commercialization of bio-based solutions. Our solutions include: Friendly™ Aedes mosquitoes genetically engineered to suppress the invasive Aedes aegypti mosquito; Arctic® apples that will not brown when bitten, sliced, or bruised; a clinically validated transcriptional gene switch to precisely control production of biotherapeutics; bovine reproductive technologies driving genetic gain for the dairy and beef industries; genetically engineered miniature swine models to provide better predictive efficacy in evaluation of new medicines; and our AquAdvantage® salmon bringing productivity benefits to the aquaculture industry through our majority-owned subsidiary AquaBounty. Intrexon’s cutting-edge platforms have broad applicability, thus opening the door to the considerable potential of engineered biology.
Intrexon and our collaborators are building solutions to challenging issues across fields as diverse as medicine, fuel, agriculture, nutrition, personal care, chemicals, and manufacturing, forging a sustainable path forward for current and future generations. We call our approach Better DNA® and invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook and LinkedIn.
240 articles with Intrexon Corporation
Intrexon Corporation announced Randal J. Kirk, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas on Wednesday, May 15th, at 3:40 p.m. Pacific Time.
Intrexon Corporation announced its first quarter financial results for 2019.
Intrexon Corporation and its majority owned Intrexon Health subsidiary Xogenex, announced that four abstracts will be presented as posters at the American Society of Gene and Cell Therapy Annual Meeting, which will be held April 29 - May 2, 2019, at the Washington Hilton in Washington, D.C.
Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper
Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries
Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference
Intrexon Corporation announced Thomas D. Reed, PhD, Founder and Chief Science Officer, will present at the Paradigm Capital Biosynthesis Conference on April 15, 2019 in Toronto.
Two therapeutic candidates from Precigen's game-changing UltraCAR-T™ therapeutic platform commencing clinical studies
Intrexon and Surterra Wellness to Collaborate on Botticelli™ Next Generation Plant Propagation for Cannabis Cultivation
Companies to advance Intrexon's Botticelli™ platform to improve efficiency in cannabis plantlet production
Intrexon Corporation, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, announced it will release fourth quarter 2018 financial results after the market closes on Thursday, February 28th, 2019.
Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference
Intrexon Corporation announced their presentation at the SVB Leerink 8th Annual Global Healthcare Conference in New York.
Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients
First-in-class therapy using autologous CAR-T cells targeting advanced ovarian cancer
Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform into Development for Cannabis
Companies to apply Intrexon's proprietary Botticelli™ platform toward rapid and sustainable cannabis plantlet production
Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that the company and its subsidiaries will present at upcoming investor conferences in San Francisco.
- Executive leadership to discuss recent announcements
Agreement enables Merck KGaA, Darmstadt, Germany, to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts
Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program
Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon
Intrexon and AquaBounty Receive Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production
Assessment by Argentina's National Advisory Commission on Agricultural Biotechnology Sets Regulatory Precedent
Quarterly GAAP revenues of $32.4 million and net loss attributable to Intrexon of $57.3 million including non-cash charges of $38.7 million
Intrexon Corporation today announced it will release third quarter 2018 financial results after the market closes on Thursday, November 8th, 2018. The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update.
ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes
A unique approach to induce immune tolerance using specifically targeted and designed ActoBiotics® Lactococcus lactis engineered to express therapeutic agents.
Establishing itself as Intrexon Bioinformatics Germany GmbH (IBG)